Haizheng Biological Materials: Shareholder Sinopec Capital Plans to Reduce Holdings by No More Than 1%

Haizheng Biological Materials Announcement: Sinopec Capital holds 10,788,200 shares, accounting for 5.32%. It plans to reduce its holdings by no more than 2,026,700 shares, or 1% of the company’s total share capital, through centralized bidding within three months after the disclosure, starting from fifteen trading days after the announcement. The reduction period is from March 17, 2026, to June 16, 2026. The share reduction price will be determined by the market price at that time. All shares were acquired before the IPO. The reason for the reduction is for operational development and funding needs.